Clinical Trial

Novel Diagnostics for Early Lyme Disease

Study Description

Novel Diagnostics for Early Lyme Disease

There are more than 300,000 new cases of Lyme disease every year in the US. Lyme disease is a dangerous bacterial infection transmitted by tick bites and it becomes increasingly severe as the infection progresses. Definitive diagnosis is based on serum-based tests that have fundamental limitations: 1) current tests cannot detect early infections so patients do not receive antibiotic therapy until the infection has progressed, and 2) there is no way to measure if antibiotic therapy has been successful. MicroB-plex will address these two unmet clinical needs by introducing a novel, blood-based diagnostic method that will enable clinicians to diagnose infections earlier and to monitor the success of their interventions.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Diagnostic Test - MicroB-plex Lyme Immunoassay

Subject's blood and clinical data are collected to develop a diagnostic immunoassay

Additional Information

Official Study Title

Novel Diagnostics for Early Lyme Disease

Clinical Trial ID

NCT03963635

ParticipAid ID

azpzqd